Ultragenyx Pharmaceutical (RARE) Accumulated Expenses (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Accumulated Expenses data on file, last reported at $57.0 million in Q1 2026.

• Quarterly Accumulated Expenses fell 67.05% year-over-year to $57.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $57.0 million (down 67.05% YoY) and the FY2025 annual result came in at $265.0 million, up 181.91% from the prior year.
• Accumulated Expenses slipped to $57.0 million in Q1 2026 per RARE's latest filing, from $265.0 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $265.0 million in Q4 2025 and bottomed at $41.6 million in Q1 2022.
• The 5-year median for Accumulated Expenses is $82.9 million (2023), against an average of $119.2 million.
• The widest annual swing landed in 2022, when Accumulated Expenses jumped 310.05%; it then slumped 67.05% in 2026.
• Tracing RARE's Accumulated Expenses over 5 years: stood at $204.7 million in 2022, then tumbled by 59.48% to $82.9 million in 2023, then rose by 13.34% to $94.0 million in 2024, then soared by 181.91% to $265.0 million in 2025, then sank by 78.49% to $57.0 million in 2026.
• Per Business Quant, the three latest RARE Accumulated Expenses figures stand at $57.0 million (Q1 2026), $265.0 million (Q4 2025), and $220.5 million (Q3 2025).

Peer Comparison